A New Era in Epicardial Access for the Ablation of Ventricular Arrhythmias: The Epi-Co


Journal

JACC. Clinical electrophysiology
ISSN: 2405-5018
Titre abrégé: JACC Clin Electrophysiol
Pays: United States
ID NLM: 101656995

Informations de publication

Date de publication:
01 2021
Historique:
received: 03 06 2020
revised: 27 07 2020
accepted: 28 07 2020
entrez: 22 1 2021
pubmed: 23 1 2021
medline: 19 8 2021
Statut: ppublish

Résumé

This multicenter registry aimed to assess the reproducibility and safety of intentional coronary vein exit and carbon dioxide insufflation to facilitate subxiphoid epicardial access in the setting of ventricular tachycardia ablation. Epicardial ablation for ventricular tachycardia is not a widespread technique due to the significant potential complications associated with subxiphoid puncture. The first experience in 12 patients showed that intentional coronary vein exit and carbon dioxide insufflation was technically feasible. A branch of the coronary sinus was cannulated by means of a diagnostic JR4 coronary catheter. Intentional perforation at the distal portion of that branch was performed with a high tip load 0.014-inch angioplasty wire. A microcatheter was advanced over the wire into the pericardial space. Carbon dioxide was then insufflated into the pericardial space, allowing direct visualization of the anterior pericardial space to facilitate subxiphoid puncture. Intentional coronary vein exit was attempted in 102 consecutive patients in 16 different centers and successfully completed in 101 patients. Significant pericardial adhesions were confirmed in 3 patients, preventing carbon dioxide insufflation and epicardial ablation. None of the punctures were complicated with inadvertent right ventricular puncture or damage to a coronary artery. Significant bleeding (>80 ml) due to coronary vein exit occurred in 5 patients, without hemodynamic compromise. None of the patients required surgery. Coronary vein exit and carbon dioxide insufflation can be safely and reproducibly achieved to facilitate subxiphoid pericardial access in the setting of ventricular tachycardia ablation.

Sections du résumé

OBJECTIVES
This multicenter registry aimed to assess the reproducibility and safety of intentional coronary vein exit and carbon dioxide insufflation to facilitate subxiphoid epicardial access in the setting of ventricular tachycardia ablation.
BACKGROUND
Epicardial ablation for ventricular tachycardia is not a widespread technique due to the significant potential complications associated with subxiphoid puncture. The first experience in 12 patients showed that intentional coronary vein exit and carbon dioxide insufflation was technically feasible.
METHODS
A branch of the coronary sinus was cannulated by means of a diagnostic JR4 coronary catheter. Intentional perforation at the distal portion of that branch was performed with a high tip load 0.014-inch angioplasty wire. A microcatheter was advanced over the wire into the pericardial space. Carbon dioxide was then insufflated into the pericardial space, allowing direct visualization of the anterior pericardial space to facilitate subxiphoid puncture.
RESULTS
Intentional coronary vein exit was attempted in 102 consecutive patients in 16 different centers and successfully completed in 101 patients. Significant pericardial adhesions were confirmed in 3 patients, preventing carbon dioxide insufflation and epicardial ablation. None of the punctures were complicated with inadvertent right ventricular puncture or damage to a coronary artery. Significant bleeding (>80 ml) due to coronary vein exit occurred in 5 patients, without hemodynamic compromise. None of the patients required surgery.
CONCLUSIONS
Coronary vein exit and carbon dioxide insufflation can be safely and reproducibly achieved to facilitate subxiphoid pericardial access in the setting of ventricular tachycardia ablation.

Identifiants

pubmed: 33478716
pii: S2405-500X(20)30711-8
doi: 10.1016/j.jacep.2020.07.027
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

85-96

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Justo Juliá (J)

Sussex Cardiac Centre, Brighton, United Kingdom. Electronic address: justojc@hotmail.com.

Fayez Bokhari (F)

King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia.

Hasso Uuetoa (H)

Sahlgrenska University Hospital, Gothenburg, Sweden.

Pawel Derejko (P)

Medicover Hospital, Warsaw, Poland; Department of Cardiac Arrhythmias, National Institute of Cardiology, Warsaw, Poland.

Vassil B Traykov (VB)

Acibadem City Clinic Tokuda Hospital, Sofia, Bulgaria.

Adrian Gwizdala (A)

First Department of Cardiology, University of Medical Sciences, Poznan, Poland.

Frederic A Sebag (FA)

Institut Mutualiste Montsouris, Paris, France.

Finn Hegbom (F)

Oslo University Hospital Rikshospitalet, Oslo, Norway.

Ole-Gunnar Anfinsen (OG)

Oslo University Hospital Rikshospitalet, Oslo, Norway.

Atif AlQubbany (A)

King Abdulaziz Medical City, Jeddah, Saudi Arabia.

Aleksander Bardyszewski (A)

Medicover Hospital, Warsaw, Poland.

Enes Elvin Gul (EE)

Madinah Cardiac Centre, Madinah, Saudi Arabia.

Valeri Geleva (V)

Acibadem City Clinic Tokuda Hospital, Sofia, Bulgaria.

Senthil Kirubakaran (S)

Queen Alexandra Hospital, Portsmouth, United Kingdom.

Steven Podd (S)

Royal Devon and Exeter Hospital, Exeter, United Kingdom.

Girish Ganesha Babu (GG)

Royal Bournemouth Hospital, Bournemouth, United Kingdom.

Richard Balasubramaniam (R)

Royal Bournemouth Hospital, Bournemouth, United Kingdom.

Phang Boon Lim (PB)

Hammersmith Hospital, London, United Kingdom.

Matthew Wright (M)

Guy's and St. Thomas' Hospital, London, United Kingdom.

Rick Veasey (R)

Eastbourne District General Hospital, Eastbourne, United Kingdom.

Ian Mann (I)

Sussex Cardiac Centre, Brighton, United Kingdom.

David Hildick-Smith (D)

Sussex Cardiac Centre, Brighton, United Kingdom.

James McCready (J)

Sussex Cardiac Centre, Brighton, United Kingdom.

John Silberbauer (J)

Sussex Cardiac Centre, Brighton, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH